Podcasts about factor viii

In this week's episode, we'll hear about new insights into PU.1-mutated agammaglobulinemia. Researchers show that haploinsufficiency of the master transcriptional regulator PU.1 causes agammaglobulinemia and dendritic cell deficiencies. These patients experience an array of infectious and non-infectious complications, but not leukemia. After that: venetoclax-based induction therapy in younger patients with AML. Venetoclax plus decitabine was associated with superior safety and non-inferior response rates compared to intensive chemotherapy. Is it time to consider lower-intensity therapy beyond older and unfit patients? Finally, a focus on venous thromboembolism. Researchers link BGAT, an enzyme pivotal to determining blood type, to risk of future VTE. They say high plasma levels of BGAT contribute to risk above and beyond what can be explained by von Willebrand factor and Factor VIII.Featured Articles:One hundred thirty-four germ line PU.1 variants and the agammaglobulinemic patients carrying themVenetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AMLHisto–blood group ABO system transferase plasma levels and risk of future venous thromboembolism: the HUNT study

In this Review Series episode on Basic/Translational Science of Factor VIII, Factor IX, and von Willebrand Factor introduced by Dr. Thomas Ortel, we'll hear from contributing authors Drs. Ben Samuelson Jones, Mac Monroe and Peter Lenting as they discuss how the functional roles of these 3 proteins are interconnected. Click here to view the complete Review Series featured in Volume 144 Issue 21 of Blood.

Tháng 05/2024, cựu thủ tướng Anh Rishi Sunak đã gửi lời xin lỗi công khai đến người dân vì một bê bối truyền máu nhiễm bệnh, khiến hàng chục nghìn người nhiễm HIV và viêm gan C. Một bê bối từ những năm 70, 80 của thế kỷ trước, mà chính ông Sunak cũng phải thừa nhận rằng đó là “sự suy thoái đạo đức kéo dài hàng thập kỷ trong lĩnh vực y tế và chăm sóc sức khỏe” của chính phủ Anh.  Sự thật được phơi bày sau nhiều thập kỷ Bê bối bắt đầu từ những năm 1970-1980 tại Anh khi có hàng ngàn người cần truyền máu. Những người này được chia thành hai nhóm chính, một là những bệnh nhân thiếu máu trong quá trình phẫu thuật, trong các điều trị y tế, hay những phụ nữ vừa sinh con… Nhóm thứ hai là những người mắc bệnh máu khó đông, một căn bệnh di truyền do thiếu hụt Yếu tố VIII hoặc IX, những yếu tố cần thiết cho quá trình tạo cục máu đông. Theo hãng tin AP, vào đầu những năm 1970, các bác sĩ đã phát hiện ra một phương pháp điều trị mới, được gọi là Yếu tố đông máu 8 (Factor VIII) và được ca tụng là phương thuốc kỳ diệu. Đây là loại thuốc được tách ra từ huyết tương người, do vậy cần một số lượng lớn nguồn cung huyết tương để sản xuất. Nhu cầu sớm vượt quá nguồn cung trong nước, vì vậy các quan chức y tế Anh đã bắt đầu nhập khẩu huyết tương từ Hoa Kỳ. Tuy nhiên, điều đáng nói là lý lịch của những người hiến máu gây nhiều lo ngại vì vào thời điểm đó, Yếu tố VIII được lấy từ máu của hàng chục ngàn người hiến tại Hoa Kỳ. Những người này hiến máu để kiếm tiền. Họ thường là tù nhân, những người làm nghề mại dâm hoặc những người nghiện. Chính điều này làm tăng đáng kể nguy cơ huyết tương bị nhiễm bệnh, mà chỉ cần một người hiến máu bị nhiễm bệnh thì toàn bộ lô sản phẩm đều sẽ bị nhiễm bệnh theo. Theo ước tính từ cuộc điều tra kéo dài 6 năm mà chính phủ của thủ tướng Theresa May ra lệnh tiến hành năm 2017, hơn 30.000 người đã nhiễm virus viêm gan C hoặc HIV qua truyền máu hoặc do điều trị bằng Yếu tố VIII. Hơn 3000 người chết và hàng chục nghìn người phải sống chung với bệnh tật. Nhiều người còn lây sang gia đình và người thân của mình. Thẩm phán Brian Langstaff, người đứng đầu cuộc điều tra về bê bối “máu bẩn”, đã tố cáo rằng thảm hoạ này hoàn toàn “không phải một tai nạn” mà bắt nguồn từ sự tác trách, coi thường tính mạng của người dân. Giới chức Anh lúc đó đã bỏ qua các cảnh báo nguy hiểm, bỏ qua các phương pháp sàng lọc và xử lý nguồn máu vì lý do kinh tế, bỏ qua cả các quy tắc đạo đức. Sai lầm nối tiếp sai lầm. Sau khi phát hiện ra những ca nhiễm HIV và viêm gan C do được truyền máu, chính phủ của cố thủ tướng Magaret Thatcher thời điểm đó, những người phải chịu trách nhiệm chính cho vụ việc này, thay vì dừng lại, nhận lỗi và sửa sai thì lại cố gắng che đậy, đưa thông tin sai sự thật đến người dân và tiêu huỷ các bằng chứng. Để rồi hơn 50 năm sau, người dân Anh mới được nhận lời xin lỗi công khai đầu tiên tới từ chính phủ Rishi Sunak. Đáng tiếc là hàng ngàn nạn nhân đã không còn sống để được nghe lời xin lỗi mà họ vẫn mong chờ.“Vô hại” “Vô hại” là những gì mà chính phủ nói với công chúng. Theo nhật báo Anh The Guardian, tháng 11/1983, cựu bộ trưởng y tế Ken Clarke đã mạnh mẽ khẳng định trước báo giới rằng “không có bằng chứng thuyết phục” nào cho thấy HIV có thể lây truyền qua đường máu và nguy cơ virus viêm gan C gây bệnh là “rất thấp và không nghiêm trọng”. Để công chúng thêm tin tưởng, các bộ trưởng cũng liên tục nhắc lại rằng người dân Anh “đang nhận được sự điều trị tốt nhất hiện có”. Báo cáo điều tra của thẩm phán Langstaff còn chỉ ra rằng các bác sĩ cũng đóng góp một phần không nhỏ công sức vào việc lừa dối người dân. Các bác sĩ không những không thông báo cho bệnh nhân những nguy cơ tiềm ẩn trước khi bệnh nhân tham gia điều trị mà thậm chí cả khi những người này đã nhiễm virus HIV hay viêm gan C, các bác sĩ cũng che giấu thông tin về nguyên nhân và tình trạng bệnh của họ, dẫn đến những chậm trễ trong việc tiếp cận điều trị chuyên khoa. “Vô trách nhiệm” “Vô trách nhiệm” là những gì công chúng nói về họ. Họ ở đây là chính phủ Anh thời điểm đó, và cụ thể hơn là Hệ thống Y tế Quốc gia Anh (National Health Service - NHS). Nhiệm vụ chủ đạo của cơ quan này là chăm sóc, nâng cao sức khoẻ cho người dân, ưu tiên và tôn trọng sinh mạng của bệnh nhân. Thế nhưng họ đã làm gì? ... Họ làm ngơ trước những hiểm hoạ mà họ biết rõ. Theo đài BBC và tờ The Guardian của Anh, ngay từ những năm 1930, người ta đã biết rõ rằng việc truyền máu có thể làm lây nhiễm nhiều loại bệnh chết người. Virus gây ra bệnh viêm gan C đã xuất hiện ít nhất từ giữa những năm 1970, còn việc lây truyền HIV qua đường máu thì đã được giới khoa học xác nhận vào năm 1982. Không chỉ vậy, họ còn biết rằng việc nhập khẩu máu và các chế phẩm máu thương mại sản xuất tại Mỹ mang nhiều rủi ro và ít an toàn hơn so với các phương pháp điều trị trong nước. Vào giữa những năm 1970, một giáo sư đã cảnh báo rằng các sản phẩm máu này được lấy “100% từ những người vô gia cư ở các khu vực tồi tàn”, trong khi đó Tổ chức Y tế Thế giới (WHO) kêu gọi các quốc gia tự chủ về nguồn máu để bảo đảm an toàn. NHS cũng tiến hành tăng quy mô của các bể chứa để sản xuất Yếu tố VIII dù biết như vậy có thể làm tăng đáng kể nguy cơ lây truyền virus. Biết rõ là vậy nhưng giới chức y tế nước này đã không có những biện pháp cần thiết để bảo vệ người dân. Họ không những không đình chỉ việc nhập khẩu các sản phẩm máu thương mại từ Mỹ, mà cũng chẳng kiểm soát việc phân phối chúng. Việc triển khai xét nghiệm virus HIV và viêm gan C trong các sản phẩm máu được hiến cũng bị trì hoãn. Chính phủ cũng không đầu tư nghiên cứu các phương pháp làm bất hoạt virus, chẳng hạn như qua xử lý nhiệt. Họ làm ngơ trước tính mạng của người dân. Dù tôn chỉ hành động là “tôn trọng mọi sinh mệnh, không phân biệt đối xử, luôn mang lòng trắc ẩn và sự tử tế” nhưng NHS đã sử dụng các học sinh khuyết tật tại trường Treloar's College như những con chuột bạch để thử nghiệm Yếu tố VIII. Vẫn theo báo cáo điều tra năm 2017, từ năm 1974 đến 1987, 122 đứa trẻ mắc bệnh máu khó đông (haemophilia) đã được điều trị tại ngôi trường này bằng phương pháp mới, một thứ phương pháp “kỳ diệu” khiến ít nhất 72 trong số này tử vong. Họ đa phần đều chết vì nhiễm HIV và các loại virus viêm gan A, B, C.  “Vô vọng” “Vô vọng” có lẽ là cảm giác mà những nạn nhân của bê bối này phải chịu đựng. Theo chân thông tín viên RFI Emeline Vin tại Anh, chúng ta sẽ cùng lắng nghe câu chuyện của chính những nạn nhân và người nhà của họ. Rất nhiều người đã chết, trong đó có Collin Smith : “Collin Smith là nạn nhân nhỏ tuổi nhất bị nhiễm bệnh. Cậu bé được chẩn đoán nhiễm Sida ngay trước sinh nhật năm hai tuổi. Mái tóc vàng và khuôn mặt tinh nghịch, cậu bé đã mất năm 1990, khi mới chỉ 7 tuổi. Bố mẹ của Collin cho biết : “Trước khi chết, thằng bé rất gầy, nó chỉ còn da bọc xương. Khi đó nó nặng 6 kg, chỉ nặng hơn đứa trẻ mới sinh một chút. Hai tháng cuối dường như kéo dài vô tận với chúng tôi. Chúng tôi rất tuyệt vọng. Chẳng đêm nào chúng tôi ngủ được. Ít nhất bây giờ chúng tôi đã đủ dũng cảm để nhắc về thằng bé. Collin có tính cách rất đặc biệt. Là một đứa trẻ vui vẻ, thằng bé lúc nào cũng tươi cười, nó thường hay trêu chọc mọi người.” Với những nạn nhân đã qua đời, nỗi đau để lại cho người thân, gia đình của họ. Vậy những người may mắn vẫn sống sót thì sao? Vào những năm 80, Bob Naylor đã được truyền máu trong một cuộc phẫu thuật và đã bị nhiễm virus viêm gan C từ đó. Bob cho biết : “Tôi thường xuyên cảm thấy không khoẻ. Cảm giác mệt mỏi, uể oải khủng khiếp. Mỗi lần tôi đi ngủ, chân tôi lại bắt đầu bị chuột rút và co thắt. Tôi đau bụng và đau lưng, những cơn đau này chẳng bao giờ biến mất. Một hôm cô y tá đã nói với tôi rằng : Bob, anh biết không, cả đời này anh sẽ phải gặp chúng tôi. Tôi hỏi vì sao thì cô ấy trả lời : Gan của anh đã bị tổn hại nên anh sẽ luôn phải đi viện kiểm tra. Anh sẽ phải lấy máu 6 tháng một lần, siêu âm 6 tháng một lần, làm xét nghiệm Fibroscan 2 đến 3 năm một lần. Anh đã bị suy gan cấp tính.” Không chỉ có những nỗi đau về thể xác, tinh thần của nạn nhân cũng bị khủng hoảng nghiêm trọng. “Vào thời điểm đó, những người nhiễm HIV đều bị kỳ thị. Tại một thành phố nhỏ ở xứ Wales, Robert đã phải chịu sự phân biệt đối xử vì bị Sida. Anh cho biết : “Tôi đã kể việc mình bị nhiễm HIV cho chị gái mình và ngay sáng hôm sau, tất cả mọi người đều biết. Trên tường nhà của chúng tôi bị sơn chữ “Gia đình SIDA”. Cửa nhà thì bị vẽ chữ X. Gia đình tôi nhận được hàng tá cuộc điện thoại yêu cầu gửi tôi ra một hòn đảo hoang. Chúng tôi đã phải bỏ trốn, như thể là tôi đã giết người vậy. Thậm chí trong gia đình tôi, có người còn nói với con cái họ rằng đừng động vào đĩa của Robert, đừng động vào cốc của Robert. Nếu chính gia đình mình còn chẳng thể cảm thông với mình thì sao tôi có thể trông đợi là những người lạ ngoài kia sẽ hiểu cho tôi.” “Vô tội”Nếu nạn nhân cảm thấy vô vọng thì những người chịu trách nhiệm chính trong vụ việc này cảm thấy gì? Có thể họ cảm thấy mình “vô tội”. Ta cần quay lại vụ bê bối tương tự, diễn ra tại Pháp vào cùng khoảng thời điểm trên. Theo Viện Nghe nhìn Quốc gia Pháp (INA), khi đứng trước toà vào tháng 01/1992, cựu bộ trưởng phụ trách các vấn đề xã hội, bà Georgina Dufoix, vẫn không can tâm và phát biểu một câu “đi vào lịch sử” rằng : “Tôi cảm thấy mình có trách nhiệm nhưng không cảm thấy mình có tội.” Dù chưa khảng khái trả lời như cựu bộ trưởng Dufoix tại Pháp, nhiều người vẫn tự hỏi rằng phải chăng giới chức Anh lúc đó cũng đã không cảm thấy tội lỗi. Vì nếu thấy có tội, thấy cắn rứt lương tâm, họ đã đứng ra chịu trách nhiệm, họ sẽ không để người dân phải chờ tới vài thập kỷ mà vẫn chưa nhận được lời xin lỗi. Xin nhắc lại rằng lời xin lỗi hồi tháng 05/2024 đến từ cựu thủ tướng vừa miễn nhiệm Rishi Sunak, chứ hoàn toàn không đến từ những quan chức trong chính phủ Anh thời điểm đó, những người trực tiếp đứng sau thảm hoạ này. Có lẽ trong bê bối này, từ “vô tội” chỉ được dành cho những nạn nhân, những người đã chết, đã nhiễm bệnh vì tin tưởng vào các bác sĩ, vào hệ thống y tế quốc gia, vào chính phủ. “Vô tội” cũng là những học sinh khuyết tật của trường Treloar's College thời điểm đó, những đứa trẻ được đem ra làm thí nghiệm.Điều đáng ngạc nhiên ở bê bối máu bẩn là nó không chỉ xảy ra ở Anh, mà còn ở rất nhiều nước khác trên thế giới, từ Pháp, Nhật Bản đến Trung Quốc. Dù quy mô của thảm hoạ khác nhau, nhưng điểm chung của tất cả các bê bối này là các quan chức thời điểm đó đã làm việc tắc trách và không tôn trọng tính mạng của người dân.

There are incredible non-invasive or minimally invasive techniques to restore joint health and avoid surgery. We will explore Dr. Bianco's path and experience in this amazing field of joint restoration and offer you simple steps that you can engage to ease pain.Upfront summary: 1. Modern technology such as stem cells and exosomes allow us to accomplish results that weren't available 10 years ago.2. You can rebuild, restore and regenerate joint health in ways that surgery cannot, such as restoring cartilage. 3. Everyone over the age of 50 has some degree of arthritis but not everyone feels pain. Having arthritis and having pain are not synonymous.4. We are going to discuss the differences between these injection therapies:· PRP – Platelet Rich Plasma, an older technology using your own growth factors.· Stem cells & exosomes offer a huge magnitude of difference over PRP and supply true healing power.· Prolotherapy – stimulates the body's natural repair process.· Ozone stimulates 3 modes of action: mitochondrial energy, detoxification, and immune system stabilization and support. It also works to animate stem cells for repair.5. Adjuncts that support and amplify these injection therapies:· Peptides – BPC-157 is a natural occurring protein that stimulates a sharp rise in repair molecules VEGF, Factor VIII, collagen, and CD34.· Glucosamine & Chondroitin – stimulates chondrocytes to generate new cartilage and create hyaluronic acid for lubrication.· MSM – antioxidant and anti-inflammatory, makes cartilage stronger.· Boswellia & Curcumin – reduce inflammation like NSAIDS but without the side effect and danger.· Joint & Body Collagen (HippEvo) – Fortigel and Tendoactive are proven elements to strengthen joints and reduce inflammation.· Hyperbaric Oxygen chamber at Huber Personalized Medicine – doubles the speed of repair for a quicker return to action. · Red light laser therapy – mitochondrial stimulation to augment repair energy

The IDF confirmed it has recovered the bodies of Shani Louk, Amit Buskila, and Itzhak Gelerenter, who were killed by Hamas at the Nova Music Festival during the October 7 attacks on Israel. About 125 hostages remain unaccounted for, with the others having been released or rescued. Meanwhile the US has confirmed the first shipment of humanitarian aid has arrived in Gaza via a temporary floating pier.As the Infected Blood Inquiry prepares to conclude on Monday, we speak to someone who contracted HIV from contaminated Factor VIII when she was five years old.And how do you measure the health of a rainforest? Researchers in Costa Rica are doing it through sound.

The topic of discussion for this episode leans more toward the scientific side but has huge clinical relevance. For today, we will be asking our expert panel to lend their experience and expertise to the topic of FVIII and FIX, which we will be discussing from several related perspectives.    Contributors: Radek Kaczmarek, PhD, MSc; University of Indiana, USA Peter Lenting, PhD; INSERM, Paris, France Ben Samuelson -Jones, M.D., PhD; CHOP Research Institute, USA Courtney Thornburg, M.D., MS; Rady Children's Hospital, UCSD, USA   Senior Advisor: Donna DiMichele, MD   Hosted & Written by: Patrick James Lynch   Featured Advertiser: Sanofi   Subscribe to the Global Hemophilia Report   Show Notes: Presenting Sponsor: Sanofi   Subscribe to the Global Hemophilia Report   Connect with the Global Hemophilia Report Global Hemophilia Report on LinkedIn Global Hemophilia Report on Twitter Global Hemophilia Report on Facebook   Connect with BloodStream Media: BloodStreamMedia.com BloodStream on Facebook  BloodStream on Twitter

Every day, across the planet, blood and plasma donations save human lives. Yet as with virtually all medical innovations, the story of blood donation has a dark side. In tonight's episode, Ben, Matt and Noel dive into the disturbing tale of a conspiracy spanning decades -- how an Arkansas prison profited from selling tainted inmate blood across the world, infecting an unknown number of people with insidious diseases. Yet there's a protagonist to this twisted narrative: it's also the story Kelly Duda, the courageous investigative journalist who spoke truth to power and brought this injustice to the public eye.They don't want you to read our book.: https://static.macmillan.com/static/fib/stuff-you-should-read/See omnystudio.com/listener for privacy information.

In the 1970s and 80s, 4,689 British haemophiliacs were treated with blood products contaminated with HIV and Hepatitis C. More than half of them have died. At the time, the medication was imported from the US where it was made from the pooled blood plasma of thousands of paid donors, including some in high-risk groups, such as prisoners. If a single donor was infected with a blood-borne virus such as hepatitis or HIV then the whole batch of medication could be contaminated. Official documents presented to the inquiry revealed this therapy was given as part of clinical trials.Jason Evans is my interviewee on this episode. He is the Director and Founder of the campaigning organisation Factor 8, which is seeking justice for the familes impacted by the scandel. Jsson is also the lead claimant in the Contaminated Blood Products Group Litigation currently before the High Court and a Core Participant in the Infected Blood Public Inquiry. Jason's Father, Jonathan, died when Jason was just four years old, in October 1993. Jonathan was infected with both Hepatitis C and HIV from infected Factor VIII blood products. Growing up without his father, it was during his teenage years that Jason began to understand the circumstances around how his father came to die from AIDS.You can find out more about the scandel and the campaign here. There is also an excellent TV documentary. Hosted on Acast. See acast.com/privacy for more information.

The plasma product Factor VIII was heralded in the 1960s as a miracle treatment that helped those with haemophilia to live fuller lives. By the 1980s it was killing them in their thousands, as the product from the US was riddled with hepatitis and AIDs. The investigative journalist Cara McGoogan pieces together the sorry tale of medical negligence, commercial greed and government failures in The Poison Line: A True Story of Death, Deception and Infected Blood. In many other countries inquiries have been held, compensation paid out and individuals sent to prison, but the victims and their families in the UK are still waiting, 40 years later. Jason Evans was just 4 years old when his father died after being infected by HIV in Factor VIII. He has dedicated his adult life to getting to the truth and is now awaiting the findings of the public inquiry which began in 2018, and is expected to publish its report in March 2024. The public health expert and physician Dr Gabriel Scally is a veteran of medical inquires – from the Bristol heart scandal to the Cervical Smear failures in Ireland. He has spent his career arguing for a system of clinical governance with a duty of candour placed not just on organisations but individual medics too. He tells Tom Sutcliffe why he thinks scandals and cover-ups continue to happen, and whether a public inquiry is the best way to get to the truth. Producer: Katy Hickman

Welcome to Ask Stago, the Podcast dedicated to provide expert answers to your expert questions in coagulation. In today's episode, our guest Tom Childs will help us to understand the goal and clinical benefits of the Factor parallelism method.   Link to previous podcasts: S1E11 – How to be more productive (part 1): implementation of a rules engine  S2E8 - World Hemophilia Day  S2E4 - How to determine factor levels in hemophilia?  Literature sources: Ma AD, Carrizosa D. Acquired factor VIII inhibitors: pathophysiology and treatment. Hematology Am Soc Hematol Educ Program 2006: 432–7 (https://ashpublications.org/hematology/article/2006/1/432/19703/Acquired-Factor-VIII-Inhibitors-Pathophysiology). Morfini M. Articular status of haemophilia patients with inhibitors. Haemophilia 2008; 14 (Suppl 6): 20–2. Gringeri A, Mantovani LG, Scalone L, Mannucci PM; COCIS Study Group. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102 (7): 2358–63 Monahan PE, Baker JR, Riske B, Soucie JM. Physical functioning in boys with hemophilia in the U.S. Am J Prev Med 2011; 41 (6 Suppl 4): S360–8. Collins PW, Chalmers E, Hart D et al.; United Kingdom Haemophilia Centre Doctors' Organization. Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDO. Br J Haematol 2013; 162 (6): 758–73 (https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.12463). Riley PW, Gallea B, Valcour A. Development and implementation of a coagulation factor testing method utilizing autoverification in a high‑volume clinical reference laboratory environment. J Pathol Inform 2017; 8: 25. Witmer C, Young G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol 2013; 4 (1): 59–72 Oldenburg J, Mahlangu JN, Kim B et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377 (9): 809–18. Florin L, Desloovere M, Devreese KML. Validation of an automated algorithm for interpretation of lupus anticoagulant testing on the Stago STA R Max (Poster). International Society on Thrombosis and Haemostasis, 2017.   Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Sam Smith explores how more than a thousand haemophiliacs in the UK acquired HIV through their treatment - in what's come to be known as the contaminated blood scandal. At the same time that the queer community was fighting the devastation and stigma of HIV in the 1980s, another community was also being profoundly affected by the AIDS crisis. Through the 1970s and 80s, around a quarter of all haemophiliacs in the UK - more than 1200 people - acquired HIV through blood products given to them as treatment for their condition. Today, fewer than 250 of those people are still alive. Mark Ward was just a child when he was put on a new treatment, Factor VIII concentrate, to help manage his haemophilia - a rare bleeding disorder which stops a person's blood from clotting properly. In this episode, Mark tells us how he and his parents came to learn he had acquired HIV and hepatitis from this treatment. He shares personal insights from the long struggle for justice that he, and thousands of others like him, have faced to see accountability for this scandal. As we hear about the claims being investigated by the public inquiry into infected blood that's happening right now, we also learn how stigma was used to divide those impacted by the HIV epidemic in the 1980s - as haemophiliacs were labelled "innocent victims", and gay men were blamed for their infections. In "A Positive Life", singer Sam Smith presents stories of HIV in the UK over the last forty years. They hear from people who remember the earliest years of the AIDS crisis; the grassroots activists and marginalised communities who came together to fight stigma and raise public awareness; and a new generation living with effective treatments for HIV in a radically-changed world. An Overcoat Media production for BBC Sounds Producer: Arlie Adlington Assistant Producer: Emma Goswell Executive Producer: Steven Rajam Sound Mixing: Mike Woolley Additional sound design: Emma Barnaby Special thanks to Jim Reed

Segunda parte del especial por los tres años al aire de Otra Mirada: Sonidos por Descubrir. Saludos y música de Cabeza de Martillo, HantaVirus, Nightwalkers, Grannada, Pigs Band, Código R, Héctor Araúz, Veladhveda, Instinto, Estado de Sitio, Factor VIII, Libertad Perdida, Mala Hierba. #OtraMirada3Años #OtraMirada #SonidosPorDescubrir #Panamá #Rock #Rockpanameño #podcast

Prophylaxis in hemophilia has led to extraordinary progress, however, recent studies suggest that although the overall musculoskeletal health of persons with hemophilia has significantly improved, the goal of attaining a level of musculoskeletal health comparable to that of the general population without hemophilia has still not been achieved. Furthermore, the impact of prophylaxis has been uneven across hemophilia populations and the promise of greater physical activity free of hemorrhage has not been entirely fulfilled. This episode explores the history, evolution, and current state of prophylaxis, and highlights the current and future areas of further investigation.   Contributors: Episode Advisors: Dr. Marilyn Manco Johnson Dr. Kathelijn Fischer   Contributors: Dr. Robert Sidonio Dr. Manuel Carcao  Dr. Maria Elisa Mancuso Susan Lynch   Senior Advisor: Dr. Donna DiMichele   Links to learn more: A history of prophylaxis in haemophilia Hemophilia A and B: Routine management including prophylaxis Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort Factor VIII replacement prophylaxis in patients with hemophilia A transitioning to adults: a systematic literature review Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens Optimising prophylaxis in haemophilia A: The ups and downs of treatment Show Notes: Presenting Sponsor: Sanofi Subscribe to the Global Hemophilia Report Connect with the Global Hemophilia Report Global Hemophilia Report on LinkedIn Global Hemophilia Report on Twitter Global Hemophilia Report on Facebook Connect with BloodStream Media: BloodStreamMedia.com BloodStream on Facebook  BloodStream on Twitter 

In this podcast episode, 3 experts answers questions on the management of hemophilia A from a live webinar. Topics include: Which patients should have pharmacokinetic-guided therapy?Toxicities with PEGylated extended half-life productsFactor VIII and bone healthFactor VIII peaks, thrombotic risk, and cardiovascular diseaseChoosing between extended half-life products and emicizumab for active patientsRole of fitusiran in the treatment paradigm if approvedPresenters:Miguel A. Escobar, MDProfessor of Medicine and PediatricsDepartment of HematologyUniversity of Texas Health Science CenterMcGovern Medical SchoolDirectorGulf States Hemophilia and Thrombophilia CenterHouston, TexasMark Reding, MDProfessor of MedicineDivision of Hematology, Oncology, and TransplantationDirectorCenter for Bleeding and Clotting DisordersUniversity of MinnesotaMinneapolis, MinnesotaGuy A. Young, MDProfessor of PediatricsDirector, Hemostasis and Thrombosis CenterChildren's Hospital Los AngelesUniversity of Southern California Keck School of MedicineLos Angeles, CaliforniaLink to full program, including downloadable slidesets, expert commentary, and on-demand webcast:https://bit.ly/3zZwP6G

Hillary and Tina cover U.S. Congressman from Florida Alcee Hastings and the Arkansas Prison Blood Scandal. For show notes and links to our sources, please click here (https://themuckpodcast.fireside.fm/articles/ep97notes).

In this episode, listen to Guy A. Young, MD, as he counsels a teenage patient with severe hemophilia A and the patient's mother on various available treatment options and strategies for optimizing hemophilia A prophylaxis and adherence. Topics include:Overcoming challenges to adherenceChoice of standard vs extended half-life factor VIII vs emicizumabSafety and efficacy data with emicizumabPresenter:Guy A. Young, MDProfessor of PediatricsDirector, Hemostasis and Thrombosis CenterChildren's Hospital Los AngelesUniversity of Southern California Keck School of MedicineLos Angeles, CaliforniaLink to full program:https://bit.ly/3FxrVk2

Coagulation Factor Disorders von Willebrand Disease A spectrum of low production to production of poorly functioning von Willebrand's Factor. von Willebrand's factor (vWF) has two major functions. vWF helps platelets to stick together in the subendothelial collagen vWF binds to and maintains Factor VIII in circulation. Factor VIII breaks down very quickly in the bloodstream […] The post S2 E081 Coagulation Disorders appeared first on Physician Assistant Exam Review.

Haemophilia is a genetic condition which is characterised by one of the blood clotting factors, usually encoded for on the X chromosome, not being encoded for properly for various reasons- whether it's a mobile genetic element inserting itself into the gene or a simple mutation. On the show today, we describe the cause and symptoms of haemophilia, as well as using the case study of Queen Victoria to show that new mutations are a surprisingly common root cause... Sources for this episode: 1) Francioli, L. C., et al. (2015), Genome-wide patterns and properties of de novo mutations in humans. Nature Genetics 47(7): 822- 826. 2) Mannucci, P. M. and Tuddenham, E. G. D. (2001), The Haemophilias- From Royal Genes to Gene Therapy. The New England Journal of Medicine 344(23): 1773- 1779. 3) Thain, M. and Hickman, M. (2014), Dictionary of Biology (Eleventh Edition). London: Penguin Books Ltd. 4) Author unknown, The Haemophilia Society (date unknown), Bleeding Disorders > Haemophilia (online) [Accessed 08/04/2021]. 5) Author unknown, Wikipedia (date unknown), Factor VIII (online) [Accessed 08/04/2021]. 6) Author unknown, Wikipedia (date unknown), Queen Victoria (online) [Accessed 08/04/2021].

En la 18ª edición de la tercera temporada de Tiempos de Radio, programa transmitido para Hispanoamérica Radio, Radio Krimen y Miami VIP, conversamos con Julio Figueroa, frontman de la banda de rock peruana Sin Sangre Ni Balas, quien nos presenta en exclusiva el nuevo single homónimo de la agrupación. Además, compartimos música de las siguientes bandas invitadas: De Colombia 🇨🇴: Whisky Way Band. De Chile 🇨🇱: fozzil y Drogartt. De Argentina 🇦🇷: Frank Psiquiatra , La Falla de Manuel y Tecu y Sus Caretas. De Panamá 🇵🇦: Factor VIII. Si quieres participar en la siguiente edición, apresúrate y contáctanos en 👇 https://linktr.ee/TiemposdeRadio El único requisito es tu entusiasmo. Copyright de grabación: Todos los derechos de la música utilizada en este podcast pertenecen a los autores, compositores o intérpretes.

Welcome to Ask Stago, the Podcast dedicated to provide expert answers to your expert questions in coagulation.  In today’s episode, our expert Paul, in honor of the upcoming World Hemophilia Day, taking place April 17, will return to our podcast series to cover clinical laboratory testing approaches for patients with inherited or acquired haemophilia.   Literature sources:  Iorio A, Stonebraker JS, Chambost H, Makris M, Coffin D, Herr C, et al.; Data and Demographics Committee of the World Federation of Hemophilia. Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries. Ann Intern Med. 2019 Oct 15;171(8):540-546.   Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, et al.; WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020 Aug;26 Suppl 6:1-158.   College of American Pathologists. Hematology and Coagulation Checklist. Northfield, IL: College of American Pathologists; 2020.    Related podcasts:   S2E4 – how to determine factor levels in hemophilia - https://www.podcastics.com/episode/62593/link/  ____________________________________________________________________________________________________________ Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice. 

In this week’s episode, we will learn more about the feasibility of combining IDH inhibitors with intensive chemotherapy in patients with newly diagnosed IDH-mutant AML, review a phenotypic and functional analysis of the inflammatory infiltrate in the Langerhans Cell Histiocytosis lesion, and discuss the results of a Phase 3 trial in patients with hemophilia A evaluating prophylactic factor replacement therapy targeting two different Factor VIII trough levels for prevention of bleeds.

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation. In today episode, our expert Alex, will discuss with us how to determine factor levels in hemophilia patients. Literature sources: Alfonso Iorio,Jeffrey S. Stonebraker, Hervé Chambost, et al. Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries. Ann Intern Med.2019;171:540-546. [Epub ahead of print 10 September 2019]. doi:10.7326/M19-1208 Blanchette, VS, Key, NS, Ljung, LR, Manco‐Johnson, MJ, van Den Berg, HM, Srivastava, A, for the Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2014; 12: 1935– 9. Baker, P., Platton, S., Gibson, C., Gray, E., Jennings, I., Murphy, P., Laffan, M. and (2020), Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis. Br. J. Haematol., 191: 347-362. https://doi.org/10.1111/bjh.16776 CLSI, Determination of coagulation factor activities using the one-stage clotting assays. 2nd edition. CLSI guideline H48. Wayne PA: Clinical and Laboratory Standards Institute, 2016. College of American Pathologists. Hematology and Coagulation Checklist. Northfield, IL: College of American Pathologists; 2018 Riley PW, Gallea B, Valcour A. Development and implementation of a coagulation factor testing method utilizing autoverification in a high‑volume clinical reference laboratory environment. J Pathol Inform 2017;8

In this episode, Michael Callaghan, MD; Miguel A. Escobar, MD; and Rebecca Kruse-Jarres, MD, MPH, answer questions from a clinician audience on topics related to hemophilia management including:Maintaining long-term musculoskeletal healthIdentifying patients most likely to benefit from pharmacokinetics-guided prophylaxisManaging combination therapies in older patients with comorbiditiesYoungest age at which patients can be considered for emicizumabDevelopment of resistance to emicizumabSwitching recombinant factor therapiesUsing bypassing agents with emicizumab for breakthrough bleeds in patients with inhibitorsPotential clinical role of extending FVIII half-life with BIVV001Considerations when dosing emicizumab monthlyPresenters:Michael Callaghan, MDAssociate ProfessorDepartment of HematologyWayne State UniversityHematologistDivision of Hematology/OncologyChildren’s Hospital of MichiganDetroit, MichiganMiguel A. Escobar, MDProfessor of Medicine and PediatricsDepartment of HematologyUniversity of Texas Health Science CenterMcGovern Medical SchoolDirectorGulf States Hemophilia and Thrombophilia CenterHouston, TexasRebecca Kruse-Jarres, MD, MPHProfessorDepartment of MedicineUniversity of WashingtonExecutive/Medical DirectorWashington Institute for CoagulationSeattle, WashingtonContent supported by educational grants from Genentech, a member of the Roche Group; Sanofi Genzyme Corporation; and Takeda Pharmaceutical Company Ltd.Link to full program, including downloadable slidesets, expert commentaries, and on-demand Webcast: http://bit.ly/2MW5uhi

Disfruta de una selección de Punk rock de Panamá. Grupos clásicos del género como Factor VIII, Caras de Hambre, o 2 huevos 1 Camino, con propuestas más nuevas como Bajón, LP, Rigangs, entre otros. Con música de Estado de Sitio, Radicales Libres, Lucyfernandez, Calibre 57, entre otros.

Go online to PeerView.com/CEV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in hemophilia discuss the use of extended half-life replacement factor VIII products for the treatment of patients with hemophilia A. Upon completion of this activity, participants will be able to: Describe the benefits and limitations of conventional replacement factor VIII regimens for the management of hemophilia A, Assess the latest clinical data regarding efficacy, safety, and tolerability of extended half-life replacement factor VIII products for the treatment of hemophilia A, Incorporate extended half-life replacement FVIII regimens into the management of patients with hemophilia A, Discuss the importance of a collaborative approach among physicians, pharmacists, and other clinicians in the management of patients with hemophilia A.

Go online to PeerView.com/CEV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in hemophilia discuss the use of extended half-life replacement factor VIII products for the treatment of patients with hemophilia A. Upon completion of this activity, participants will be able to: Describe the benefits and limitations of conventional replacement factor VIII regimens for the management of hemophilia A, Assess the latest clinical data regarding efficacy, safety, and tolerability of extended half-life replacement factor VIII products for the treatment of hemophilia A, Incorporate extended half-life replacement FVIII regimens into the management of patients with hemophilia A, Discuss the importance of a collaborative approach among physicians, pharmacists, and other clinicians in the management of patients with hemophilia A.

Go online to PeerView.com/CEV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in hemophilia discuss the use of extended half-life replacement factor VIII products for the treatment of patients with hemophilia A. Upon completion of this activity, participants will be able to: Describe the benefits and limitations of conventional replacement factor VIII regimens for the management of hemophilia A, Assess the latest clinical data regarding efficacy, safety, and tolerability of extended half-life replacement factor VIII products for the treatment of hemophilia A, Incorporate extended half-life replacement FVIII regimens into the management of patients with hemophilia A, Discuss the importance of a collaborative approach among physicians, pharmacists, and other clinicians in the management of patients with hemophilia A.

Go online to PeerView.com/CEV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in hemophilia discuss the use of extended half-life replacement factor VIII products for the treatment of patients with hemophilia A. Upon completion of this activity, participants will be able to: Describe the benefits and limitations of conventional replacement factor VIII regimens for the management of hemophilia A, Assess the latest clinical data regarding efficacy, safety, and tolerability of extended half-life replacement factor VIII products for the treatment of hemophilia A, Incorporate extended half-life replacement FVIII regimens into the management of patients with hemophilia A, Discuss the importance of a collaborative approach among physicians, pharmacists, and other clinicians in the management of patients with hemophilia A.

Go online to PeerView.com/CEV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in hemophilia discuss the use of extended half-life replacement factor VIII products for the treatment of patients with hemophilia A. Upon completion of this activity, participants will be able to: Describe the benefits and limitations of conventional replacement factor VIII regimens for the management of hemophilia A, Assess the latest clinical data regarding efficacy, safety, and tolerability of extended half-life replacement factor VIII products for the treatment of hemophilia A, Incorporate extended half-life replacement FVIII regimens into the management of patients with hemophilia A, Discuss the importance of a collaborative approach among physicians, pharmacists, and other clinicians in the management of patients with hemophilia A.

Go online to PeerView.com/CEV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in hemophilia discuss the use of extended half-life replacement factor VIII products for the treatment of patients with hemophilia A. Upon completion of this activity, participants will be able to: Describe the benefits and limitations of conventional replacement factor VIII regimens for the management of hemophilia A, Assess the latest clinical data regarding efficacy, safety, and tolerability of extended half-life replacement factor VIII products for the treatment of hemophilia A, Incorporate extended half-life replacement FVIII regimens into the management of patients with hemophilia A, Discuss the importance of a collaborative approach among physicians, pharmacists, and other clinicians in the management of patients with hemophilia A.

Go online to PeerView.com/CEV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in hemophilia discuss the use of extended half-life replacement factor VIII products for the treatment of patients with hemophilia A. Upon completion of this activity, participants will be able to: Describe the benefits and limitations of conventional replacement factor VIII regimens for the management of hemophilia A, Assess the latest clinical data regarding efficacy, safety, and tolerability of extended half-life replacement factor VIII products for the treatment of hemophilia A, Incorporate extended half-life replacement FVIII regimens into the management of patients with hemophilia A, Discuss the importance of a collaborative approach among physicians, pharmacists, and other clinicians in the management of patients with hemophilia A.

Go online to PeerView.com/CEV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in hemophilia discuss the use of extended half-life replacement factor VIII products for the treatment of patients with hemophilia A. Upon completion of this activity, participants will be able to: Describe the benefits and limitations of conventional replacement factor VIII regimens for the management of hemophilia A, Assess the latest clinical data regarding efficacy, safety, and tolerability of extended half-life replacement factor VIII products for the treatment of hemophilia A, Incorporate extended half-life replacement FVIII regimens into the management of patients with hemophilia A, Discuss the importance of a collaborative approach among physicians, pharmacists, and other clinicians in the management of patients with hemophilia A.

En este episodio 29 de El Poste del Neo Travel Cast tenemos música de LAPM, Ataque de Sonido y Tumbas además de las últimas noticias del punk, ska y hardcore en Colombia. Ya están todos los episodios en todas las plataformas (Apple Podcasts, Spotify, Stitcher, Google, y muchas mas!). Por favor sigan enviando sus noticias, conciertos, lanzamientos y sobre todo, comentarios. Un agradecimiento especial a Daniel Tello por participar en este episodio. MÚSICA LAPM – Creo en mi Ataque de Sonido – Violencia x Violencia Tumbas – Dolor NOTICIAS Medellin nos mostró lo mejor de su música en Ciudad Altavoz 2020 Factor VIII lanzó el sencillo ‘Palabras’ y celebran 25 años de trayectoria En Contra de Todo muestran que son ‘Eternos e Inquebrantables’ en su nuevo video Desde Costa Rica, Malas Palabras hacen de su segundo disco un trabajo introspectivo y existencial Psikiatría critica el discurso de ‘Independencia’ en una canción NOFX va a tocar ‘White trash, two heebs and a bean’ por completo desde el patio de Fat Mike ATENCIÓN: SI SU BANDA DE SKA, PUNK O HARDCORE (EN CUALQUIERA DE SUS SUBGÉNEROS) VA A LANZAR MÚSICA. CONTÁCTENOS Y LA ESTRENAMOS EN ESTE PROGRAMA. LO MISMO NOTICIAS Y CONCIERTOS. TODO DE TODA COLOMBIA ENTRA EN ESTE SHOW POR FAVOR: DARLE LIKE, COMENTAR, REPOSTEAR, DECIRLE A TUS AMIGOS, CONOCIDOS, ETC. EN ESTE ESPACIO CABEMOS TODOS Y ESPERAMOS QUE TODOS LO HAGAN SUYO PARA DAR A CONOCER EL TRABAJO DE TANTOS COMPOSITORES, MÚSICOS Y PERSONAS QUE SE EXPRESAN CON ESTA MÚSICA. --- Support this podcast: https://anchor.fm/neotravelcast/support

On today's episode we discuss: — Climate: A review of health-related workplace absenteeism in the United States during the pandemic found that workplace absenteeism during the pandemic had only increased in certain occupational subgroups: personal care service, healthcare support, and food processing. The authors postulate that this is due to the close interpersonal contact experienced in these occupations which creates a higher risk of COVID-19 transmission. — Epidemiology: A case report describes an 11-year-old boy who presented with symptoms of Guillain-Barre Syndrome three weeks after COVID-19 infection. The authors discuss that Guillain-Barre is a rare but documented phenomenon in adult COVID-19 patients but believe this to be one of the first descriptions of the condition in a pediatric patient. — Understanding the Pathology: A study of lab values in COVID-19 positive patients admitted to the ICU at Tongji hospital, Wuhan observed 12 thrombotic events in 9 patients with coagulation abnormalities which included lower natural anticoagulants, elevated Factor VIII, and presence of anti-phospholipid antibodies. In near-terminal patients, Factors V and VII were lower and prothrombin time was prolonged. These results suggest elevated Factor VIII and presence of anti-phospholipid antibodies may be involved in the etiopathology of COVID-19 hypercoagulable status, while lower Factor V and VII and prolonged PT may indicate advancing illness. — Management: A systematic review and meta-analysis of 22 observational cohort studies on renal complications in COVID-19 found that acute kidney injury was the most widely reported renal complication followed by need for renal replacement therapy, electrolyte disturbances, and acidosis. Meta-regression found a significant association between preexisting chronic kidney disease and COVID-19 associated acute kidney injury suggesting increased risk in these patients. — R&D Diagnosis and Treatment: American pathologists developed and evaluated immunohistochemical and in situ hybridization assays for tissue identification of SARS-CoV-2. They validated their methods through staining of COVID-19 autopsy samples including 8 lungs, 1 placenta, and 10 kidneys finding their protocols to be sensitive and specific for the virus. They provide protocols and reagent lists so that other pathology labs could easily replicate these techniques to study SARS-CoV-2 distribution across tissue types, allowing for a better understanding of tissue-specific pathogenesis. --- Support this podcast: https://anchor.fm/covid19lst/support

https://waveform-particle-state.blogspot.com/ There have been several after death events in my life. The first one I can recall was about age 7 in 1945 a few years after my uncle was killed in the US Army as described in another blog post. The other events happened much more closely to the actual date of the death of a friend or family member and were just brief encounters such as a smell or an unexpected encounter with a bird. The first event that clearly changed my life is described below. The editor described below is Charles T. Tart, Ph.D. This article first appeared on his website, T.A.S.T.E., The Archives of Scientists' Transcendent Experiences.Anthony Chipoletti (real name) graduated from the University of Pittsburgh in 1980 with a BS degree that included training in Chemistry, Biology and Psychology. He was employed for a time in Pittsburgh in 1968 as a medical research technician in hematology and hemophilia research with Jessica Lewis, who discovered Factor VIII. Financial and family needs kept him from further graduate education and he was employed as a researcher in the media industry. This Beyond the Light article was first published on T.A.S.T.E., The Archives of Scientists' Transcendent Experiences. http://www.issc-taste.org/arc/dbo.cgi?set=expom&id=00042&ss=1 The website of the third person, Nancy Clark https://www.freewebs.com/nancy-clark/

After working in the hospital for 6 years, Dr. Jess Peatross decided to leave her job and pursue further education in Functional Medicine. Her passion for preventive care and her search to find more tools to help heal her patients drove her down this path of self improvement and furthering her education. Now, she has the power to give her patients the best of both worlds with her training in both western medicine as an MD as well as Functional Medicine. During her Functional Medicine training, she really began to understand and research the medicinal power of CBD and cannabis. Today, we’re picking her brain on CBD, cannabis and how sift through the BS on the market.  In this episode you’ll learn: How Dr. Jess’ experience in internal medicine and as a hospitalist led her to dig deeper into finding the root causes of chronic disease  About the process that prescription drugs and medical devices go through to get “approved”  Why it’s important to question the motive behind medical studies  What exactly CBD is About the many uses and benefits of using CBD as medicine How to find high quality CBD and pinpoint the right dose for you What “full spectrum” CBD means How to spot a good CBD  Why topical CBD balms work to help decrease inflammation  About the difference between CBD and cannabis  The difference between CBD from hemp and from cannabis How THC with CBD can help to fight cancer  How THC can affect developing brains in young adults How CBD can affect pregnant women/new mothers  How medical marijuana has been linked to lower narcotic use and death in some studies  What the endocannabinoid system is  How micro-dosing psilocybin has been shown to help some with addiction  @dr.jess.peatross | Nourish Medical Center San Diego | Online Education with Dr. Jessica Peatross  Resources / Links: Bayer sold HIV-risky meds - Factor VIII concentrate - https://www.cbsnews.com/news/bayer-sold-hiv-risky-meds/ Caught selling a blood-clotting product that stopped potentially fatal bleeding in hemophiliacs but was linked to the risk of HIV infection. New York Times reported that it sold millions of dollars worth of an older version of the medication in Latin America and Asia while marketing a newer, safer product in the United States and Europe: https://www.nytimes.com/2003/05/22/business/2-paths-of-bayer-drug-in-80-s-riskier-one-steered-overseas.html

Factor VIII Gene Therapy Clinical Trials Update by ISTH

Scottish doctor, writer, speaker, and outspoken cholesterol sceptic Malcolm Kendrick is back on the podcast this week. He continues to challenge the widespread use of statin medications, despite being targeted personally and professionally by those opposing his message. Since we last talked he has authored a new book, A Statin Nation: Damaging Millions in a Brave New Post-health World, elucidating his position against mainstream medicine’s rampant cholesterol-lowering tactics.  On this podcast, Dr. Kendrick describes in detail exactly what he believes drives the process of cardiovascular disease, informed from 35 years of research on the subject.  He explains specifically why cholesterol has been misunderstood, and how medicine got it wrong. We discuss corruption in medical research and the money supporting the status quo, and Dr. Kendrick shares some of the best ways to avoid heart disease (which have little to do with diet!). Here’s the outline of this interview with Malcolm Kendrick: [00:00:07] Our first podcast with Malcolm Kendrick: Why Cholesterol Levels Have No Effect on Cardiovascular Disease (And Things to Think about Instead). [00:00:30] Book: A Statin Nation: Damaging Millions in a Brave New Post-health World, by Dr. Malcolm Kendrick. His previous two books: Doctoring Data and The Cholesterol Con. [00:02:00] Causes vs processes. [00:03:40] History behind his journey and questioning authority. [00:07:30] Articles written by Elspeth Smith. [00:09:00] Karl Rokitansky’s paper discussing an alternative way of looking at CVD: A manual of pathological anatomy, Vol. 4. Day GE, trans. London: Sydenham Society, 1852:261; in print here. [00:09:06] Rudolf Virchow, researcher who pointed to cholesterol in artery walls. [00:10:55] Researcher Nikolai N. Anichkov: fed rabbits a high-cholesterol diet and cholesterol appeared in their arteries (sort of). [00:12:07] Ancel Keys; blaming saturated fat. [00:14:11] France - highest saturated fat consumption, lowest rate of CVD. Georgia - lowest sat fat consumption, highest rate of CVD.  See graph, here. [00:15:16] International Network of Cholesterol Skeptics (THINCS). Study: Ravnskov, Uffe, et al. "Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: a systematic review." BMJ open 6.6 (2016): e010401. [00:16:50] Pleiotropic effects of statins. [00:17:29] Movie: 12 Angry Men (1957). [00:20:30] Robert Ross - response to injury hypothesis; Study: Ross, Russell, John Glomset, and Laurence Harker. "Response to injury and atherogenesis." The American journal of pathology 86.3 (1977): 675. [00:20:40] TV show: Stranger Things. [00:22:31] Infectious disease hypothesis. [00:22:52] Analogy of rust in the paint of a car; Sickle Cell Disease as an example. [00:27:12] 14-year old boy with Sickle Cell and atherosclerosis; Study: Elsharawy, M. A., and K. M. Moghazy. "Peripheral arterial lesions in patient with sickle cell disease." EJVES Extra 14.2 (2007): 15-18. [00:28:57] Endothelial progenitor cells, produced in the bone marrow, discovered in 1997. [00:29:31] Pig study of endothelial turnover: Caplan, Bernard A., and Colin J. Schwartz. "Increased endothelial cell turnover in areas of in vivo Evans Blue uptake in the pig aorta." Atherosclerosis 17.3 (1973): 401-417. [00:31:48] Vitamin C's role in maintaining collagen and blood vessels. [00:33:08] Lp(a) molecules - patching cracks in the artery walls. [00:33:42] Depriving guinea pigs of vitamin C caused atherosclerosis; Study: Willis, G. C. "The reversibility of atherosclerosis." Canadian Medical Association Journal 77.2 (1957): 106. [00:34:24] Linus Pauling - said CVD was caused by chronic low-level vitamin C deficiency. [00:35:53] What else damages endothelial cells? Many things, including smoking, air pollution, high blood sugar, Kawasaki disease, sepsis/infection. [00:41:19] Glycocalyx; Nitric oxide. [00:43:30] Health benefits of sun exposure. [00:44:26] Biomechanical stress (blood pressure) - atherosclerosis in arteries but not in veins. [00:47:57] Things that interfere with repair: steroids, vascular endothelial growth factor (VEGF) inhibitors. [00:55:00] The effects of stress on the cardiovascular system. [00:57:55] Red blood cells are what brings cholesterol into blood clots. [00:58:59] Cholesterol crystals in atherosclerotic plaques come from red blood cells. Study: Kolodgie, Frank D., et al. "Intraplaque hemorrhage and progression of coronary atheroma." New England Journal of Medicine 349.24 (2003): 2316-2325. [01:00:55] Very low-density lipoproteins (VLDLs) are procoagulant; High-density lipoprotein (HDL) is anticoagulant. [01:03:46] Familial hypercholesterolemia (FH); Factor VIII. [01:08:15] Cholesterol-lowering pharmaceuticals; Repatha. In the clinical trial, the total number of cardiovascular deaths was greater in the Repatha group than the placebo group. Study: Sabatine, Marc S., et al. "Evolocumab and clinical outcomes in patients with cardiovascular disease." New England Journal of Medicine 376.18 (2017): 1713-1722. [01:09:34] David Deamer, biologist and Research Professor of Biomolecular Engineering. [01:10:05] Karl Popper, philosopher. [01:10:28] Bradford Hill’s Criteria for Causation. [01:13:52] Michael Mosley, BBC journalist. [01:16:40] Statin denialism - an internet cult with deadly consequences? [01:19:18] The money behind the statin and low-fat industries. [01:20:06] Margarine; Trans-fatty acids, banned in several countries. [01:24:37] The impact of food; The focus on food to the exclusion of other pillars of health. [01:26:38] Dr. Phil Hammond; CLANGERS [01:28:21] Avoiding internet attacks. [01:32:00] ApoA-1 Milano. Original study: Nissen, Steven E., et al. "Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial." Jama 290.17 (2003): 2292-2300. [01:33:05] The Heart Protection (HPS) Study in the UK: Heart Protection Study Collaborative Group. "MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo controlled trial." The Lancet 360.9326 (2002): 7-22. [01:33:36]  Scandinavian Simvastatin Survival Study (4S) Scandinavian Simvastatin Survival Study Group. "Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)." The Lancet 344.8934 (1994): 1383-1389. [01:33:49] West of Scotland Coronary Prevention Study (WOSCOPS): Shepherd, James, et al. "Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia." New England Journal of Medicine 333.20 (1995): 1301-1308. [01:34:21] National Institute of Health’s ALLHAT-LLT trial: Officers, A. L. L. H. A. T. "Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)." JAMA 288.23 (2002): 2998-3007. [01:34:50] 2005 - Regulations guiding clinical trials changed. [01:35:14] Negative antidepressant studies not published; Study: Turner, Erick H., et al. "Selective publication of antidepressant trials and its influence on apparent efficacy." New England Journal of Medicine 358.3 (2008): 252-260. [01:37:11] Minnesota Coronary Experiment (MCE): Analysis of recovered data: Ramsden, Christopher E., et al. "Re-evaluation of the traditional diet-heart hypothesis: analysis of recovered data from Minnesota Coronary Experiment (1968-73)." bmj 353 (2016): i1246. [01:39:44] Why Most Published Research Findings Are False: Ioannidis, John PA. "Why most published research findings are false." PLoS medicine 2.8 (2005): e124. [01:39:55] Richard Horton, editor of the Lancet: half of what is published is not true: Horton, Richard. "Offline: What is medicine’s 5 sigma." Lancet 385.9976 (2015): 1380. [01:41:11] The problem with reproducibility; a database of clinical trials that cannot be challenged or reproduced. [01:42:37] Editors of prominent journals losing faith in published research: Marci Angell, Richard Smith [01:44:55] Parachute study: Yeh, Robert W., et al. "Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial." bmj 363 (2018): k5094. [01:46:01] Benefits that are major are obvious; no randomized clinical trial necessary. [01:48:33] Preventing vs. screening. [01:51:42] Podcast: Movement Analysis and Breathing Strategies for Pain Relief and Improved Performance with physical therapist Zac Cupples. [01:51:59] Analysis of women who died in various ways, examining breast tissue; found that a high % of women had what you could diagnose as breast cancer. Study: Bhathal, P. S., et al. "Frequency of benign and malignant breast lesions in 207 consecutive autopsies in Australian women." British journal of cancer 51.2 (1985): 271. [01:53:34] Screening programs not associated with reduced CVD or death; Study: Krogsbøll, Lasse T., et al. "General health checks in adults for reducing morbidity and mortality from disease: Cochrane systematic review and meta-analysis." Bmj 345 (2012): e7191. [01:54:26] Coronary Artery Calcium (CAC) scan. Podcast: Coronary Artery Calcium (CAC): A Direct Measure of Cardiovascular Disease Risk, with Ivor Cummins. [01:54:46] Cardiologist Bernard Lown.  [01:58:38] People who had measles/mumps less likely to get CVD; Study: Kubota, Yasuhiko, et al. "Association of measles and mumps with cardiovascular disease: The Japan Collaborative Cohort (JACC) study." Atherosclerosis 241.2 (2015): 682-686. [02:00:55] Life expectancy in US and UK is now falling. [02:06:46] Physical health doesn't exist without social health and psychological health. [02:07:40] Negative Twitter messages correlate with rates of heart disease; Study: Eichstaedt, Johannes C., et al. "Psychological language on Twitter predicts county-level heart disease mortality." Psychological science 26.2 (2015): 159-169. [02:09:58] People who take statins believe they’re protected so they stop exercising. Study: Lee, David SH, et al. "Statins and physical activity in older men: the osteoporotic fractures in men study." JAMA internal medicine 174.8 (2014): 1263-1270. [02:11:45] Simple changes: make friends, have good relationships, speak to your kids, exercise, eat natural food, sunshine. [02:16:53] Blood sugar measurements following funny lecture vs. boring lecture; Study: Hayashi, Keiko, et al. "Laughter lowered the increase in postprandial blood glucose." Diabetes care 26.5 (2003): 1651-1652. [02:18:08] Dr. Malcolm Kendrick’s blog.

Quinto programa de Otra Mirada por Radio 10, 88.1 FM en Panamá (www.radio10pty.com). Segunda parte de PolítiRock, titulada "PolítiRock 2". Rock latinoamericano con mensaje político. Música de Factor VIII, Todos Tus Muertos, Alux Nahual, Caifanes, Plastilina Mosh, Maldita Vecindad y los Hijos del Quinto Patio, Sociedad Anónima, entre otros. No te pierdas Otra Mirada todos los miércoles a las 8 pm en Radio 10.

Session 99 Today, Dr. Aaron Shmookler joins us who has an interestingly different type of specialty. He is a pathologist trained Blood Banking & Transfusion Medicine specialist. A year and a half out of training now, he serves in an academic setting in West Virginia. Thank you for listening to us! Please check out all our other available resources on Meded Media. [01:48] Interest in Blood Banking and Transfusion Medicine Aaron took a transitional year and started his residency in Neurology. But he realized something was missing – the lab. He went into pathology really enjoying the field. Then he finished his Pathology residency and quickly realized he also missed taking care of patients on the bedside. So he subspecialized in Transfusion Medicine and Blood Banking that has the bedside aspect of care. Then he also gets to do the laboratory side where he works behind the scenes. [04:14] Traits that Lead to Being a Good Blood Banking & Transfusion Medicine Specialist In this specialty, you have to be detail-oriented, very specific, and concise. This is generally true in the field of pathology as well. What got him initially interested in Neurology was when he began caring for patients with Alzheimer's disease. Specifically, he was interested in localizing lesions. [06:35] Types of Patients At the bedside, they perform a procedure called apheresis. He describes it as an "oil change" to patients. So if you have a patient with sickle cell disease, they can be chronically dependent on blood transfusions. One of the ways they can be treated is by exchanging their abnormal red cells and transfusing them with normal red cells. The procedure can take a couple of hours. When the problem is with the patient's plasma, they'd also take out the plasma and given them back new plasma. Nevertheless, there's a whole slew of guidelines put out by the American Society for Apheresis. This would give you an idea of the kinds of conditions they would be treating and see what kinds of patients they encounter. Aaron is also in charge of all the blood products dispensed in their hospital. This refers to whoever who needs blood such as emergency patients who come in with trauma or surgical patients in the OR. They also give blood to obstetric patients, basically, anyone who needs a blood product. [08:55] The Role of a Physician in a Blood Bank As someone in charge of the blood bank, a physician makes sure that all blood products that come out are going to be compatible with the patient who is going to receive the blood product. One of the ways to do this is to make sure patients haven't developed any antibodies to some of the antigens in red cells. If they have, he makes sure he's able to find units of blood that would be negative for those antibodies. Sometimes, they might not be able to work up with the patient's antigen status. As a result, they may need to release blood emergently. In this case, they caution physicians who require that blood that they haven't really completed all the testing they need to do to find the best-matched blood for that. An example of this would be cases of patients bleeding significantly and they can't wait for any testing and they'd have to transfuse something. They're able to provide special blood for this, but they can't guarantee this wouldn't cause an adverse effect. So they have to be mindful of these particular conditions. They also manage factors. Factor VIII, for instance, is used to treat patients with hemophilia. They also make sure the doses are appropriate. [11:35] Typical Day, Procedures, & Taking Calls For Aaron, a typical day would be coming to work and following up on any patients that may have come in at night that required a significant amount of blood. Aaron also takes some time to teach residents and conduct research. Part of his training includes clinical pathology. In terms of procedures, Aaron does apheresis. This involves the help of a nurse to run an apheresis machine and he oversees all of it as it's happening. They also have standard operating procedures such as making sure that when they issue blood, the nurses are able to transfuse it in the right way. They also have to oversee procedures that their blood bank technologists are doing. So while not directly hands-on, they're definitely overseeing a lot of the procedures that other people are doing. Aaron takes about 6-8 weeks of call. A lot of the calls come from the blood bank. They can ask him about whatever questions they may have. They're mostly blood bank-related questions although it can be specimen-related questions. [15:50] The Training Path After medical school, you can do whatever you want for residency. Specifically, there are residencies that may tend themselves toward wanting to become a transfusion medicine physician such as pathology. In fact, the board certification exam for Blood Banking and Transfusion Medicine is offered by the American Board of Pathology. Physicians who are also training in Anesthesiology may be interested in Transfusion Medicine as well as Hematology Oncology and Emergency Medicine. In terms of competitiveness, Transfusion Medicine is not as competitive. Looking at the 2019 residency match data, there were 924 applicants for 601 pathology positions. About 95% of them were filled. This is nearly 3 physicians for U.S. senior. So 93% of U.S. seniors who apply were matched. [18:05] Subspecialty Opportunities You can subspecialize in just about everything. You may like to subspecialize in another subspecialty that's a little bit closer to clinical pathology such as Microbiology or Clinical Chemistry. [19:10] Working with DOs, Primary Care, and Other Specialties Aaron explains that there's an increase of DOs that have been reported to going into Pathology. That said, he doesn't think there is any bias against DOs. Other specialties they interact with include primary care physicians and general surgeons. They help select the most appropriate tests. They make sure that the resources are utilized in a cost-effective manner without harming the patient. They want to make sure they're giving patients what they need. They also see to it that blood is being used appropriately. Often, they give blood unnecessarily. There has been a lot of data to show that a restrictive transfusion strategy can be beneficial compared to a more liberal transfusion strategy. The less you can give somebody, the better it can actually be in certain clinical situations. Studies have shown that a transfusion of blood is independently associated with increased mortality. Hence, this has to be utilized in the right setting. Aaron's job, therefore, is to make sure that the blood being distributed is used appropriately. [22:30] Special Opportunities Outside of Clinical Medicine Blood Banking and Transfusion Medicine Specialists can function as medical directors and other doctors of other blood donor centers. Teaching is another route they can take. [24:15] What He Wished He Knew Going into this Specialty Aaron actually took this subspecialty relatively late in the process so he wished he had known about this earlier. He also wished he knew about pathology earlier. What he likes most about his specialty is both the patient side and the laboratory side of things. On the flip side, what he likes the least is they're often undervalued or unnoticed by the administrators and even patients. That said, they lack the support, resources, and the basic facilities they need compared to more money-making surgical specialties, Additionally, as a pathologist, the workload can get busy resulting in slower than expected turnaround times which can delay care. Otherwise, haste makes waste and that could result in a significant error that can seriously harm the patient. [27:00] Community vs. Academic Setting Being part of a donor center would mean being very much out in the community. As a pathology trained transfusion specialist, you would be a pathologist practicing in the community. With additional training in blood banking, you'd be able to address a lot of calls. As a result, you could be put in charge of the community blood bank. [28:08] Major Changes in the Future Specifically, in blood banking and transfusion medicine, they're bringing back whole blood. They used to give whole blood in the military. They still do. But since World War II, they've developed the ability to provide more component therapy. This means they're able to give only red cells if they only need red cells. Or give only plasma if they only need plasma, and so on. This has a lot of benefits. But they also realized that in the trauma setting, whole blood actually has been very beneficial. In the pathology side of things, they have a lot of emerging hot topics such as artificial intelligence, digital pathology, liquid biopsies, and next-generation sequencing. These are fancy technologies that supplement the microscope. The microscope has been used since the late 16th century and it will continue to be used for the foreseeable future. On the negative side, there is a shortage of physicians in the U.S. and pathology is no exception. In fact, Aaron read a 2013 article offering a predictive model examining some of the factors influencing pathology workforce supply in the U.S. In the coming two decades, it's projected that there will be a decrease from 5.7 to 3.7 full-time equivalent pathologist for 100,000 population. They're actually looking at a deficit of more than 5,700 full-time equivalent pathologists. Aaron believes that artificial intelligence would be an adjunct and it would never replace the pathologists. He doesn't anything could come close to replicating the human eye. But when AI can help in the digital pathology perspective, this could be very useful for them. [33:05] Final Words of Wisdom Aaron says that if he had to do it all over again, he would still have chosen the same specialty. He encourages students to look into pathology. Out of all the medical disciplines, he thinks that pathology offers the most subspecialties. There's the clinical side of things and more! Finally, he encourages medical students and physicians to take care of themselves. Think of medicine as this journey on the expressway. So enjoy the scenery and reflect on the vehicle you're riding. Links: Meded Media Guidelines - American Society for Apheresis

Paula James, MD, FRCPC and Professor in the Department of Medicine, Division of Hematology at Queen’s University joins us to share insights about the groundbreaking research conducted in her lab with Master’s student, Victoria Candy which explores why female genetic carriers of hemophilia A often experience abnormal bleeding. Listeners gain insight into the research process Continue Reading

This month on The BloodStream Podcast, Clive Smith and the UK Haemophilia Society provide an update on the inquiry into the UK’s Contaminated Blood Scandal, Amy Board joins to discuss her new role with Ask The Expert and Believe Limited, Natalie discusses a recent article on how to “invest” in your health, Patrick recaps a the HemAware story on New York Rangers Coach Dan Quinn, and we introduce a new segment: Mama Sue’s Netflix Recs. All that and more on Episode 32 of The BloodStream Podcast!   Presenting Sponsor: Shire   Latest Ask The Expert Podcast   Latest Powering Through Podcast   Leave us a review on iTunes!  Help others from BloodStream!   Community News In 60 Seconds: Hepatitis C Virus Is Major Predictor of Liver Cancer in Hemophilia, U.S. Inpatient Data Reveals BIVV001 Increases Half-life of Factor VIII in People with Severe Hemophilia A, Phase 1/2a Trial Shows Novoeight Safe, Effective in Hemophilia A Patients Over Long Term, Phase 3b Trial Shows Preventive Use of Idelvion Lets Kids with Hemophilia B Need Fewer Infusions, Trial Shows Catalyst Announces Updates on Two Lead Compounds for Hemophilia Like Segment: The Right Way to Invest in Your Health   Comment Segment: New York Rangers Coach David Quinn on Hockey and Hemophilia   Interview Segment: Amy Board, the new host of Ask The Expert!   BloodFeed: https://www.bloodfeed.com Connect with BloodStream: Email mailbag@bloodstreammedia.com Find all of our bleeding disorders podcasts on BloodStreamMedia.com BloodStream Facebook Page BloodStream Twitter Account   Subscribe to BloodStream: iTunes: http://bit.ly/bloodstreamitunes Stitcher: http://bit.ly/bloodstreamstitcher LibSyn: http://bit.ly/bloodstreamlibsyn SoundCloud: http://bit.ly/bloodstreamSC TuneIn: http://bit.ly/bloodstreamtunein Google Play: http://bit.ly/bloodstreamPlay Spotify: http://spoti.fi/2nNPhui